2019 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Slide7of 50FromSC Johnson, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.

New Antiretroviral Agents and Combinations: 2018-2019

Agent/Regimen

Comments

Bictegravir-FTC-TAF

Single tablet regimen (STR)

3TC-TDF

Generic combination

Doravirine-3TC-TDF

New STR with NNRTI

Dolutegravir-3TC

New STR with 2 drugs

Doravirine

New NNRTI

Efavirenz-3TC-TDF

Generic STR with efavirenz

Efavirenz 400-3TC-TDF

STR with lower dose of EFV

Darunavir-COBI-FTC-TAF

First PI-based STR

Ibalizumab-uiyk

IV monoclonal antibody

IM Cabotegravir/rilpivirine and oral cabotegravir

Injectable regimen; pending FDA approval in late December 2019

Slide8of 50FromSC Johnson, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.

Initiating Antiretroviral Therapy

FromSCJohnson,MDatNewOrleans,LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICAL CONFERENCE, IAS  USA.